These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 15298530)

  • 1. Advancements in the treatment of psoriasis: role of biologic agents.
    Rich SJ; Bello-Quintero CE
    J Manag Care Pharm; 2004; 10(4):318-25. PubMed ID: 15298530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
    Weinberg JM
    Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining traditional agents and biologics for the treatment of psoriasis.
    Cather JC; Menter A
    Semin Cutan Med Surg; 2005 Mar; 24(1):37-45. PubMed ID: 15900797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
    Brimhall AK; King LN; Licciardone JC; Jacobe H; Menter A
    Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic therapies for psoriasis. A systematic review.
    Boehncke WH; Prinz J; Gottlieb AB
    J Rheumatol; 2006 Jul; 33(7):1447-51. PubMed ID: 16724367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States.
    Anis AH; Bansback N; Sizto S; Gupta SR; Willian MK; Feldman SR
    J Dermatolog Treat; 2011 Apr; 22(2):65-74. PubMed ID: 20443663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new era in the management of psoriasis? The biologics: facts and controversies.
    Ferrándiz C; Carrascosa JM; Boada A
    Clin Dermatol; 2010; 28(1):81-7. PubMed ID: 20082956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic agents in the treatment of psoriasis.
    Guarneri F; Guarneri C; Guarneri B
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):193-217. PubMed ID: 19075983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of biologic therapies for plaque psoriasis.
    Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
    Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004.
    Guenther L; Langley RG; Shear NH; Bissonnette R; Ho V; Lynde C; Murray E; Papp K; Poulin Y; Zip C
    J Cutan Med Surg; 2004; 8(5):321-37. PubMed ID: 15868311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic options.
    Leon A; Nguyen A; Letsinger J; Koo J
    Expert Opin Pharmacother; 2007 Apr; 8(5):617-32. PubMed ID: 17376017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologic therapeutics in the treatment of psoriasis. Part 1: review.
    Langley RG; Gupta AK; Cherman AM; Inniss KA
    J Cutan Med Surg; 2007; 11(3):99-122. PubMed ID: 17511926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of systemic therapies for moderate to severe psoriasis.
    Sizto S; Bansback N; Feldman SR; Willian MK; Anis AH
    Br J Dermatol; 2009 Jun; 160(6):1264-72. PubMed ID: 19120346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
    Weinberg JM; Saini R; Tutrone WD
    J Drugs Dermatol; 2002 Dec; 1(3):303-10. PubMed ID: 12851990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
    Reich K; Burden AD; Eaton JN; Hawkins NS
    Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologicals in the treatment of psoriasis.
    Boker A; Kimball AB; Rolz-Cruz G
    Curr Opin Investig Drugs; 2007 Nov; 8(11):939-46. PubMed ID: 17979028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials].
    Zhang Z; Schmitt J; Wozel G; Kirch W
    Med Klin (Munich); 2009 Feb; 104(2):125-36. PubMed ID: 19242664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatments for psoriasis and the risk of malignancy.
    Patel RV; Clark LN; Lebwohl M; Weinberg JM
    J Am Acad Dermatol; 2009 Jun; 60(6):1001-17. PubMed ID: 19344980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.
    Weinberg JM; Bottino CJ; Lindholm J; Buchholz R
    J Drugs Dermatol; 2005; 4(5):544-55. PubMed ID: 16167412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.